Game-Changer: New MOU Sparks Rapid Growth in Plasma Medicine Industry
In a significant move towards enhancing healthcare in Iran, a trilateral memorandum of understanding (MOU) has been established to elevate the country’s role in the plasma medicine industry. This initiative is a crucial step in integrating new technologies into healthcare systems, aiming to improve patient outcomes and access to advanced medical treatments.
Signed by key officials including Saeed Sarkar from the Vice-Presidency for Science and Technology, Shahin Akhoundzadeh from the Ministry of Health, and Mahdiyeh Bakhtiari, the CEO of the Plasma Therapy Knowledge-Based Company, the MOU focuses on several critical objectives:
- Developing and implementing extensive multi-center research in plasma medicine.
- Integrating advanced technology into official treatment protocols across the nation.
- Conducting impactful projects to treat hard-to-cure diseases.
- Improving health services and providing access to cutting-edge medical technologies.
This memorandum signifies a national movement that harnesses the scientific, research, and technological capabilities of Iran. It aims to expand the use of emerging technologies within the medical field, which is essential for advancing healthcare standards.
First Indigenous Plasma Therapy Clinic
In a parallel development, the Atomic Energy Organization of Iran (AEOI), in collaboration with Jahrom University of Medical Sciences in southern Fars province, inaugurated the first cold plasma therapy clinic tailored for wound treatment using domestic technology. Launched in April, this clinic represents a significant milestone in the application of plasma therapy in the country.
During the clinic’s opening ceremony, AEOI head Mohammad Eslami emphasized the achievement as a testament to Iran’s scientific progress and national self-confidence. He pointed out that nuclear technology is pivotal not only in medical services but also in agriculture.
Eslami remarked, “The inauguration of this clinic can help expand plasma therapy technology in other medical centers in the country.” This initiative is expected to pave the way for utilizing nuclear technologies in cancer treatment and other health areas, as expressed by Hossein Hakimelahi, chancellor of Jahrom University of Medical Sciences.
Advancements in Plasma Medicine
On August 26, Eslami highlighted that advancements in heavy water derivatives and plasma medicine are ushering in new possibilities for drug development and medical treatments. This reflects a significant leap in applying nuclear technology to enhance public health.
Under the auspices of a new MOU with the Ministry of Health, clinical trials that were previously centralized at Tehran University will now extend to select universities nationwide. Eslami stated, “This will accelerate the spread of plasma-based technologies to different provinces, ensuring that all Iranians can benefit equally and simultaneously from these advances.”
These comments were made during National Doctors Day celebrations, where Eslami also shared the AEOI’s notable success in producing over 70 types of radiopharmaceuticals. These are currently supplied to more than 220 nuclear medicine centers across Iran and are even exported internationally.
The produced radiopharmaceuticals can be categorized into three main types:
- Diagnostic: These advancements are pushing the frontiers of knowledge and improving the precision of patient examinations.
- Therapeutic: This category focuses on alleviating patients’ suffering while providing more effective treatment options.
- Palliative: These products are essential for enhancing the quality of life for patients with serious illnesses.
Eslami further revealed that around 20 additional radiopharmaceuticals are currently under research and in clinical trial phases. This reflects Iran’s expanding capability to integrate nuclear science into its healthcare system, positioning the country at the forefront of medical innovation.
The developments in plasma medicine and radiopharmaceutical production mark a significant advancement in Iran’s healthcare landscape, promising improved patient care and treatment options for various medical conditions.
